Mocetinostat (class I/IV HDAC inhibitor) and durvalumab were given to sixty-three patients with advanced NSCLC across cohorts stratified by tumor PD-L1 expression and prior experience with ICI regimens. This evidence concerns the gene CD274 and non-small cell lung carcinoma.